

Opzelura - (1.5%; Cream)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | Ruxolitinib Phosphate | Innovator | Incyte |
| Dosage | 1.5%; Cream | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | OPZELURA is a Janus kinase (JAK) inhibitor indicated for: • the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. • the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.